Dupixent® (dupilumab) sbla accepted for fda priority review for treatment of copd with type 2 inflammation

Priority review granted based on positive results from two phase 3 trials; i f approved, dupixent would be the only biologic therapy for copd and the first new treatment approach for this disease in more than a decade
REGN Ratings Summary
REGN Quant Ranking